May 26, 2017: Maybe it’s just the normal shifts of top jobs in biopharma, but Cambridge, Mass.-based Biogen seems to be a bit of a revolving door at the top recently. In the latest news, Kenneth DiPietro, Biogen’s exec VP of HR, announced he is stepping down.
May 26, 2017: Juno failed CAR-T therapy JCAR015, cost the company $46.4M, according to analyst calculations. In March, Juno pulled the plug on JCAR015, a once-promising CAR-T treatment.
May 26, 2017: The year has gone fairly well so far for the biopharma industry, despite inconsistent messages from the Trump administration about drug pricing. Lee Jackson takes a look at five big pharma companies that are facing big decisions this year.
May 26, 2017: Two weeks after his confirmation, new FDA Commissioner Scott Gottlieb is already hard at work looking to hire additional staff.